AI in Life Science Analytics Market

AI in Life Science Analytics Market Outlook 2035

The global AI in life science analytics market size was valued at US$ 1.6 Bn in 2024 and is projected to reach US$ 4.9 Bn by 2035, expanding at a CAGR of 10.9% from 2025 to 2035. The main factors leading to this expansion are the fast implementation of AI and big data analytics in genomics, proteomics, and drug-discovery workflows; rising expenditure on precision and personalized medicine, which needs valuable insights from large, heterogeneous datasets; and increasing need for real-world evidence and advanced analytics to enhance clinical trials and regulatory submissions.

• The AI in life science analytics market reached US$ 1.6 Bn in 2024.
• The market is estimated to reach US$ 4.9 Bn by 2035
• The AI in life science analytics industry is anticipated to expand at a CAGR of 10.9% from 2025 to 2035.
• Top companies in the market include Indegene, Lexalytics, Databricks, SAS Institute Inc., IQVIA, IBM.
• North America dominated the market in 2024, holding the largest revenue share of 47.2% in 2024
• By end-user, the pharmaceutical and biotechnology companies held the major market share of 48.5% in 2024

Analysts’ Viewpoint regarding Global AI in Life Science Analytics Market

The global AI in life science analytics market is bound to witness rapid growth over years due to the rapid digital transformation of the pharma, biotech, and healthcare sectors. It is expected that the integration of AI in life science analytics will significantly impact the way companies decipher complex biological and clinical data, with the whole process being much faster and more accurate results being generated.

AI-powered analytics platforms are expected to be the major enablers of the life science sector in the near future as companies are putting more efforts to improve drug discovery efficiency, optimize clinical trials, and enhance patient outcomes through data-driven insights. Additionally, the market growth will be fueled by the increasing focus on personalized medicine as well as the numerous collaborations between technology providers and life science companies.

Moreover, the next developments of machine learning algorithms and cloud-based analytical tools are expected to significantly simplify data processing and predictive modeling in the life sciences. In general, analysts consider the market to be moving in a powerful upward direction, with AI-powered analytics being able to create new opportunities, improve efficiency, and give a competitive advantage to the entire global life sciences ecosystem.

AI in Life Science Analytics Market Introduction

The AI in life science analytics market is one of the fastest-growing segments of the healthcare and biotechnology industries. It is a field where AI technologies are progressively employed to get insightful data from complicated and large biological data. The market refers to the use of advanced analytics, machine learning, and predictive modeling in various areas of life sciences such as drug discovery, genomics, clinical research, and patient care management.

With Al, data analysis is automated and pattern recognition is enhanced. Researchers and organizations can thus innovate at a faster pace, increase precision, and at the same time, take well-informed decisions all along the product development lifecycle. The massive amounts of healthcare and biological data, in addition to the demand for quick, data-based solutions, are the main reasons for the worldwide life sciences industry to get extensively involved in Al-powered analytics.

However, the merging of Al with cloud computing, big data platforms, and real-world evidence systems is going to the next level of the scalability and the speed of the analytical processes. Consequently, the Al in life science analytics market is on its way to be the main instrument that will radically change the face of the research, help to operationalize the workflows efficiently, and be the source of the subsequent revolutionary wave of precision medicine and healthcare delivery.

For instance, the World Health Organization (WHO), in collaboration with key partners and supporters, launched version 2.0 of the Epidemic Intelligence from Open Sources (EIOS) system, used globally for the early detection of public health threats. It helps public health teams detect and respond to potential threats daily by analyzing large volumes of publicly available information in near real time.

Attribute	Detail
Market Drivers	Drug Discovery and Development Demand for Treating Complex Diseases

Drug Discovery and Development Propelling AI in Life Science Analytics Market

The traditional pharmaceutical drug discovery and development process is being completely transformed by artificial intelligence with its time and cost savings of the process. By the use of sophisticated algorithms and machine learning models, Al has the capacity to sift through huge datasets-such as genomic data, molecular structures, or clinical trial results in order to pinpoint the most effective therapeutic compounds with an improved accuracy level.

With this data-driven approach, researchers can foresee drug-target interactions, refine molecular structures, and select candidates that have the highest chances of success. By implementing Al in operations that are usually time-consuming and are thus done only in limited amounts, such as screening, validation and optimization, the early stages of drug discovery are not only rapidly advanced but also the whole development pipeline becomes more efficient, which is the ultimate goal of the pharmaceutical industry.

For instance, in the U.S., the ARPA-H (Advanced Research Projects Agency for Health) under DHHS (Department of Health and Human Services) has mentioned that it had inaugurated its MATRIX venture, a bold Al-powered repurposing of drugs program aimed at rare and neglected diseases. The project is using advanced machine-learning models to pinpoint new uses of drugs in a way that is faster than the usual R&D route, thereby indicating that the federal government is increasingly putting money into Al-powered healthcare innovation.

Demand for Treating Complex Diseases Accelerating AI in Life Science Analytics Market

The rising occurrence of complicated and chronic diseases such as cancer, neurological disorders, and autoimmune illnesses is going to be one of the primary reasons that will generate a demand for new pharmaceuticals. As the treatments for these diseases usually involve complex biological mechanisms and large datasets from genomics, proteomics, and clinical research, traditional research methods alone are already inadequate.

Al is addressing problems that human beings put forward is by increasing efficiency in data analysis with such huge data sets and giving precise drug targets and also suggesting exact patient responses. Hence, it is contributing to the rapid progression of medicine in general and targeted therapy in particular, and thus, Al has become necessary for survival in humanity's fight against the most difficult diseases of the world.

Additionally, the incorporation of Al-powered analytics opens up possibilities for scientists to simulate the progression of diseases and the results of treatments, thus, lessening the need for a long and arduous trial-and-error process. With healthcare systems and pharma companies increasingly concentrating on precision medicine, the use of Al in fighting intricate illnesses is anticipated not only to extend dramatically but also to change the speed and the effectiveness of drug development in the 21st century fundamentally.

For instance, in the UK, the Department for Science, Innovation and Technology (DSIT) revealed that it would spend £82.6 Mn in February 2025 on a major funding initiative for supporting Al-driven projects that aim to provide cancer care and drug discovery. This move is a vital component of the UK government's extensive plan of strengthening the country's position as a front-runner in health tech and precision medicine.

Segment Outlook of AI in Life Science Analytics Market

Pharmaceutical and Biotechnology Companies represent the largest end-user segment of the AI in life science analytics market with 48.5% share. In their quest for innovation and market leadership, these organizations produce tons of clinical, research, and operational data, thus, they have become the first and most significant users of AI-powered ​analytics.

Their​

AI in Life Science Analytics Market Outlook 2035

The global AI in life science analytics market size was valued at US$ 1.6 Bn in 2024 and is projected to reach US$ 4.9 Bn by 2035, expanding at a CAGR of 10.9% from 2025 to 2035. The main factors leading to this expansion are the fast implementation of AI and big data analytics in genomics, proteomics, and drug-discovery workflows; rising expenditure on precision and personalized medicine, which needs valuable insights from large, heterogeneous datasets; and increasing need for real-world evidence and advanced analytics to enhance clinical trials and regulatory submissions.

• The AI in life science analytics market reached US$ 1.6 Bn in 2024.
• The market is estimated to reach US$ 4.9 Bn by 2035
• The AI in life science analytics industry is anticipated to expand at a CAGR of 10.9% from 2025 to 2035.
• Top companies in the market include Indegene, Lexalytics, Databricks, SAS Institute Inc., IQVIA, IBM.
• North America dominated the market in 2024, holding the largest revenue share of 47.2% in 2024
• By end-user, the pharmaceutical and biotechnology companies held the major market share of 48.5% in 2024

Analysts’ Viewpoint regarding Global AI in Life Science Analytics Market

The global AI in life science analytics market is bound to witness rapid growth over years due to the rapid digital transformation of the pharma, biotech, and healthcare sectors. It is expected that the integration of AI in life science analytics will significantly impact the way companies decipher complex biological and clinical data, with the whole process being much faster and more accurate results being generated.

AI-powered analytics platforms are expected to be the major enablers of the life science sector in the near future as companies are putting more efforts to improve drug discovery efficiency, optimize clinical trials, and enhance patient outcomes through data-driven insights. Additionally, the market growth will be fueled by the increasing focus on personalized medicine as well as the numerous collaborations between technology providers and life science companies.

Moreover, the next developments of machine learning algorithms and cloud-based analytical tools are expected to significantly simplify data processing and predictive modeling in the life sciences. In general, analysts consider the market to be moving in a powerful upward direction, with AI-powered analytics being able to create new opportunities, improve efficiency, and give a competitive advantage to the entire global life sciences ecosystem.

AI in Life Science Analytics Market Introduction

The AI in life science analytics market is one of the fastest-growing segments of the healthcare and biotechnology industries. It is a field where AI technologies are progressively employed to get insightful data from complicated and large biological data. The market refers to the use of advanced analytics, machine learning, and predictive modeling in various areas of life sciences such as drug discovery, genomics, clinical research, and patient care management.

With Al, data analysis is automated and pattern recognition is enhanced. Researchers and organizations can thus innovate at a faster pace, increase precision, and at the same time, take well-informed decisions all along the product development lifecycle. The massive amounts of healthcare and biological data, in addition to the demand for quick, data-based solutions, are the main reasons for the worldwide life sciences industry to get extensively involved in Al-powered analytics.

However, the merging of Al with cloud computing, big data platforms, and real-world evidence systems is going to the next level of the scalability and the speed of the analytical processes. Consequently, the Al in life science analytics market is on its way to be the main instrument that will radically change the face of the research, help to operationalize the workflows efficiently, and be the source of the subsequent revolutionary wave of precision medicine and healthcare delivery.

For instance, the World Health Organization (WHO), in collaboration with key partners and supporters, launched version 2.0 of the Epidemic Intelligence from Open Sources (EIOS) system, used globally for the early detection of public health threats. It helps public health teams detect and respond to potential threats daily by analyzing large volumes of publicly available information in near real time.

Attribute	Detail
Market Drivers	Drug Discovery and Development Demand for Treating Complex Diseases

Drug Discovery and Development Propelling AI in Life Science Analytics Market

The traditional pharmaceutical drug discovery and development process is being completely transformed by artificial intelligence with its time and cost savings of the process. By the use of sophisticated algorithms and machine learning models, Al has the capacity to sift through huge datasets-such as genomic data, molecular structures, or clinical trial results in order to pinpoint the most effective therapeutic compounds with an improved accuracy level.

With this data-driven approach, researchers can foresee drug-target interactions, refine molecular structures, and select candidates that have the highest chances of success. By implementing Al in operations that are usually time-consuming and are thus done only in limited amounts, such as screening, validation and optimization, the early stages of drug discovery are not only rapidly advanced but also the whole development pipeline becomes more efficient, which is the ultimate goal of the pharmaceutical industry.

For instance, in the U.S., the ARPA-H (Advanced Research Projects Agency for Health) under DHHS (Department of Health and Human Services) has mentioned that it had inaugurated its MATRIX venture, a bold Al-powered repurposing of drugs program aimed at rare and neglected diseases. The project is using advanced machine-learning models to pinpoint new uses of drugs in a way that is faster than the usual R&D route, thereby indicating that the federal government is increasingly putting money into Al-powered healthcare innovation.

Demand for Treating Complex Diseases Accelerating AI in Life Science Analytics Market

The rising occurrence of complicated and chronic diseases such as cancer, neurological disorders, and autoimmune illnesses is going to be one of the primary reasons that will generate a demand for new pharmaceuticals. As the treatments for these diseases usually involve complex biological mechanisms and large datasets from genomics, proteomics, and clinical research, traditional research methods alone are already inadequate.

Al is addressing problems that human beings put forward is by increasing efficiency in data analysis with such huge data sets and giving precise drug targets and also suggesting exact patient responses. Hence, it is contributing to the rapid progression of medicine in general and targeted therapy in particular, and thus, Al has become necessary for survival in humanity's fight against the most difficult diseases of the world.

Additionally, the incorporation of Al-powered analytics opens up possibilities for scientists to simulate the progression of diseases and the results of treatments, thus, lessening the need for a long and arduous trial-and-error process. With healthcare systems and pharma companies increasingly concentrating on precision medicine, the use of Al in fighting intricate illnesses is anticipated not only to extend dramatically but also to change the speed and the effectiveness of drug development in the 21st century fundamentally.

For instance, in the UK, the Department for Science, Innovation and Technology (DSIT) revealed that it would spend £82.6 Mn in February 2025 on a major funding initiative for supporting Al-driven projects that aim to provide cancer care and drug discovery. This move is a vital component of the UK government's extensive plan of strengthening the country's position as a front-runner in health tech and precision medicine.

Segment Outlook of AI in Life Science Analytics Market

Pharmaceutical and Biotechnology Companies represent the largest end-user segment of the AI in life science analytics market with 48.5% share. In their quest for innovation and market leadership, these organizations produce tons of clinical, research, and operational data, thus, they have become the first and most significant users of AI-powered ​analytics.

Their​ imperative to speed up drug discovery, make trials more efficient, and improve decision-making has put them in a position where they are the first to use advanced analytical tools extensively. Consequently, this segment is ahead of medical device manufacturers in terms of market ​leadership.

Their​ leadership is largely powered by a higher investment capacity and a very strong emphasis on digital transformation across R&D and commercial functions. Consequently, pharma and biotech companies remain the main drivers of AI implementation in the entire life sciences ​ecosystem.

Regional Outlook of AI in Life Science Analytics Market

Attribute	Detail
Leading Region	North America

The major part of the global Al in life science analytics market is held by North America, which is anticipated to be the most influential region during the forecast period with 47.2% market share. The regions dominance in the market can mainly be credited to the wide and deep applications of high-tech, mature healthcare, and pharmaceutical industries, as well as the hefty investments in the research and development pertaining to artificial intelligence. Specifically, the U.S. is responsible for the major part due to the widespread use of innovative gene delivery methods, large-scale financing for genomics and personalized medicine, and an increasing number of clinical trials for gene and cell therapies.

Moreover, a strong regulatory system and a series of beneficial government programs, along with quite a few collaborations between the academic world, the industry, and the public sector have made the continent a leader in this field for a long time already. In fact, the region is able to quickly innovate and broadly deploy Al-based analytics throughout the life sciences ecosystem due to the extensive data integration and computational analysis that are supported by a large number of cloud service providers and advanced digital infrastructure.

For instance, OTTAWA, to solidify the Greater Toronto Area's leadership in advanced life science analytics, Innovation, Science and Economic Development Canada (ISED), made the announcement on March 7, 2025 that the Al Compute Access Fund will be launched to support SMEs with a grant of up to CA $ 300 Mn to gain access to a high-performance computing capacity.

Analysis of Key Players in AI in Life Science Analytics Market

Indegene, Lexalytics, Databricks, SAS Institute Inc., IQVIA, IBM, Sorcero, Inc., Axtria, Medidata, Sisense Ltd., Tempus AI, Inc., Oracle, Accenture, Parexel International (MA) Corporation, Microsoft, and others are some of the leading manufacturers operating in the global AI in Life Science Analytics Market.

Each of these companies has been profiled in the AI in life science analytics market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.

AI in Life Science Analytics Market Key Developments

• In September 2025, Inovalon launched a new data and analytics offering on Snowflake's AI Data Cloud for Healthcare & Life Sciences. This partnership provides payers and life sciences organizations secure, near real-time access to Inovalon's primary source data and advanced analytics.
• In January 2024, Cleveland Clinic and IBM researchers released a strategy using AI for identifying new immunotherapy targets. This marks the initial peer-reviewed publication stemming from their Discovery Accelerator partnership, which aims to upgrade healthcare and life sciences research.
• In April 2024, IQVIA and Salesforce announced broadening their global partnership to hasten the development of the Life Sciences Cloud. This collaboration integrates IQVIA OCE innovations with Salesforce's platform, offering customers a comprehensive engagement solution.
• In June 2024, Medidata introduced Clinical Data Studio, a comprehensive platform that consolidates data from both - Medidata and external sources. This technology enables stakeholders to manage data quality effectively, expedite trial processes, and make quicker decisions by providing a complete view of data and risk strategies.

AI in Life Science Analytics Market Snapshot

Attribute	Detail
Size in 2024	US$ 1.6 Bn
Forecast Value in 2035	More than US$ 4.9 Bn
CAGR	10.9 %
Forecast Period	2025-2035
Historical Data Available for	2020-2023
Quantitative Units	US$ Bn for Value
AI in Life Science Analytics Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape	Competition Matrix Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Segmentation	By Component Software Hardware Services By Deployment Cloud On Premise By Application Research and Development Supply Chain Analytics Others By End-user Medical Devices Manufacturers Pharmaceutical and Biotechnology Companies Others
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain The Netherlands China India Japan South Korea Australia ASEAN Brazil Mexico Argentina GCC Countries South Africa
Companies Profiled	Indegene Lexalytics Databricks SAS Institute Inc. IQVIA IBM Sorcero, Inc. Axtria Medidata Sisense Ltd. TempusAI, Inc. Oracle Accenture Parexel International (MA) Corporation Microsoft Other Prominent Players
Customization Scope	Available upon request
Pricing	Available upon request

imperative to speed up drug discovery, make trials more efficient, and improve decision-making has put them in a position where they are the first to use advanced analytical tools extensively. Consequently, this segment is ahead of medical device manufacturers in terms of market ​leadership.

Their​ leadership is largely powered by a higher investment capacity and a very strong emphasis on digital transformation across R&D and commercial functions. Consequently, pharma and biotech companies remain the main drivers of AI implementation in the entire life sciences ​ecosystem.

Regional Outlook of AI in Life Science Analytics Market

Attribute	Detail
Leading Region	North America

The major part of the global Al in life science analytics market is held by North America, which is anticipated to be the most influential region during the forecast period with 47.2% market share. The regions dominance in the market can mainly be credited to the wide and deep applications of high-tech, mature healthcare, and pharmaceutical industries, as well as the hefty investments in the research and development pertaining to artificial intelligence. Specifically, the U.S. is responsible for the major part due to the widespread use of innovative gene delivery methods, large-scale financing for genomics and personalized medicine, and an increasing number of clinical trials for gene and cell therapies.

Moreover, a strong regulatory system and a series of beneficial government programs, along with quite a few collaborations between the academic world, the industry, and the public sector have made the continent a leader in this field for a long time already. In fact, the region is able to quickly innovate and broadly deploy Al-based analytics throughout the life sciences ecosystem due to the extensive data integration and computational analysis that are supported by a large number of cloud service providers and advanced digital infrastructure.

For instance, OTTAWA, to solidify the Greater Toronto Area's leadership in advanced life science analytics, Innovation, Science and Economic Development Canada (ISED), made the announcement on March 7, 2025 that the Al Compute Access Fund will be launched to support SMEs with a grant of up to CA $ 300 Mn to gain access to a high-performance computing capacity.

Analysis of Key Players in AI in Life Science Analytics Market

Indegene, Lexalytics, Databricks, SAS Institute Inc., IQVIA, IBM, Sorcero, Inc., Axtria, Medidata, Sisense Ltd., Tempus AI, Inc., Oracle, Accenture, Parexel International (MA) Corporation, Microsoft, and others are some of the leading manufacturers operating in the global AI in Life Science Analytics Market.

Each of these companies has been profiled in the AI in life science analytics market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.

AI in Life Science Analytics Market Key Developments

• In September 2025, Inovalon launched a new data and analytics offering on Snowflake's AI Data Cloud for Healthcare & Life Sciences. This partnership provides payers and life sciences organizations secure, near real-time access to Inovalon's primary source data and advanced analytics.
• In January 2024, Cleveland Clinic and IBM researchers released a strategy using AI for identifying new immunotherapy targets. This marks the initial peer-reviewed publication stemming from their Discovery Accelerator partnership, which aims to upgrade healthcare and life sciences research.
• In April 2024, IQVIA and Salesforce announced broadening their global partnership to hasten the development of the Life Sciences Cloud. This collaboration integrates IQVIA OCE innovations with Salesforce's platform, offering customers a comprehensive engagement solution.
• In June 2024, Medidata introduced Clinical Data Studio, a comprehensive platform that consolidates data from both - Medidata and external sources. This technology enables stakeholders to manage data quality effectively, expedite trial processes, and make quicker decisions by providing a complete view of data and risk strategies.

AI in Life Science Analytics Market Snapshot

Attribute	Detail
Size in 2024	US$ 1.6 Bn
Forecast Value in 2035	More than US$ 4.9 Bn
CAGR	10.9 %
Forecast Period	2025-2035
Historical Data Available for	2020-2023
Quantitative Units	US$ Bn for Value
AI in Life Science Analytics Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape	Competition Matrix Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Segmentation	By Component Software Hardware Services By Deployment Cloud On Premise By Application Research and Development Supply Chain Analytics Others By End-user Medical Devices Manufacturers Pharmaceutical and Biotechnology Companies Others
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain The Netherlands China India Japan South Korea Australia ASEAN Brazil Mexico Argentina GCC Countries South Africa
Companies Profiled	Indegene Lexalytics Databricks SAS Institute Inc. IQVIA IBM Sorcero, Inc. Axtria Medidata Sisense Ltd. TempusAI, Inc. Oracle Accenture Parexel International (MA) Corporation Microsoft Other Prominent Players
Customization Scope	Available upon request
Pricing	Available upon request

Frequently Asked Questions

How big was the global AI in life science analytics market in 2024?

The global AI in life science analytics market was valued at US$ 1.6 Bn in 2024

How big will the global AI in life science analytics industry be in 2035?

The global AI in life science analytics industry is projected to reach more than US$ 4.9 Bn by the end of 2035

What are the factors driving the AI in life science analytics market?

Drug discovery and development and demand for treating complex diseases are some of the factors driving the expansion of AI in life science analytics market.

What will be the CAGR of the global AI in life science analytics industry during the forecast period?

The CAGR is anticipated to be 10.9 % from 2025 to 2035

Which region will account for a major share of the AI in life science analytics sector during the forecast period?

North America is expected to account for the largest share from 2025 to 2035

Who are the prominent players in the global AI in life science analytics market?

Indegene, Lexalytics, Databricks, SAS Institute Inc., IQVIA, IBM, Sorcero, Inc., Axtria, Medidata, Sisense Ltd., Tempus AI, Inc., Oracle, Accenture, Parexel International (MA) Corporation, Microsoft and other prominent players.